• Je něco špatně v tomto záznamu ?

Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry

M. Nekulova, J. Holcakova, R. Nenutil, R. Stratmann, P. Bouchalova, P. Müller, L. Mouková, PJ. Coates, B. Vojtesek,

. 2013 ; 463 (3) : 415-425.

Jazyk angličtina Země Německo

Typ dokumentu hodnotící studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14050887

Grantová podpora
NT13794 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online Plný text

NLK ProQuest Central od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2003-01-01 do Před 1 rokem

The TP63 gene gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (ΔNp63) of an N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value for certain tumour types, but investigations have been hampered by a lack of well characterized antibodies and the inability to discriminate between these N-terminal isoforms with opposite functional properties. We have extensively characterized a series of monoclonal antibodies to recombinant human TAp63 and two commercial p63 monoclonals by Western blot, immunostaining and phage display epitope mapping. Twenty-eight of 29 (96.6 %) novel monoclonals that recognized all p63 isoforms showed substantial cross-reactivity with p73, as did the commercial antibody, 4A4. One novel clone, PANp63-6.1, showed slight cross-reaction with p73 by Western blotting but not immunohistochemistry and the SFI-6 monoclonal did not cross-react with p73 or p53. Phage display revealed that the PANp63-6.1 epitope has one amino acid difference between p63 and p73, the 4A4 epitope is identical in both, whereas the SFI-6 epitope is unique to p63, accounting for these findings. We also produced and characterized a TAp63-specific clone that does not recognize p53 or p73, and we prepared polyclonal sera specific for ΔNp63 isoforms. Immunohistochemistry demonstrated that TAp63 is expressed in a variety of epithelial and other cell types during development, often in a converse pattern to ΔNp63, but has a very limited expression in normal adult tissues and is independent of ΔNp63. TAp63 was expressed in 17.6 % of squamous cancers of cervix that expressed p63, unlike normal cervix where TAp63 was not expressed. TAp63 did not associate with proliferative index, but cervical carcinomas with TAp63 expression showed improved survival. These data highlight the need for rigorous antibody characterization and indicate that p63-isoform identification may improve the clinical value of p63 expression analyses.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14050887
003      
CZ-PrNML
005      
20191021125236.0
007      
ta
008      
140401s2013 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-013-1459-4 $2 doi
035    __
$a (PubMed)23887585
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Nekulová, Marta $7 xx0228718
245    10
$a Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry / $c M. Nekulova, J. Holcakova, R. Nenutil, R. Stratmann, P. Bouchalova, P. Müller, L. Mouková, PJ. Coates, B. Vojtesek,
520    9_
$a The TP63 gene gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (ΔNp63) of an N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value for certain tumour types, but investigations have been hampered by a lack of well characterized antibodies and the inability to discriminate between these N-terminal isoforms with opposite functional properties. We have extensively characterized a series of monoclonal antibodies to recombinant human TAp63 and two commercial p63 monoclonals by Western blot, immunostaining and phage display epitope mapping. Twenty-eight of 29 (96.6 %) novel monoclonals that recognized all p63 isoforms showed substantial cross-reactivity with p73, as did the commercial antibody, 4A4. One novel clone, PANp63-6.1, showed slight cross-reaction with p73 by Western blotting but not immunohistochemistry and the SFI-6 monoclonal did not cross-react with p73 or p53. Phage display revealed that the PANp63-6.1 epitope has one amino acid difference between p63 and p73, the 4A4 epitope is identical in both, whereas the SFI-6 epitope is unique to p63, accounting for these findings. We also produced and characterized a TAp63-specific clone that does not recognize p53 or p73, and we prepared polyclonal sera specific for ΔNp63 isoforms. Immunohistochemistry demonstrated that TAp63 is expressed in a variety of epithelial and other cell types during development, often in a converse pattern to ΔNp63, but has a very limited expression in normal adult tissues and is independent of ΔNp63. TAp63 was expressed in 17.6 % of squamous cancers of cervix that expressed p63, unlike normal cervix where TAp63 was not expressed. TAp63 did not associate with proliferative index, but cervical carcinomas with TAp63 expression showed improved survival. These data highlight the need for rigorous antibody characterization and indicate that p63-isoform identification may improve the clinical value of p63 expression analyses.
650    _2
$a adenokarcinom $x diagnóza $x imunologie $7 D000230
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $x diagnostické užití $x imunologie $7 D000911
650    _2
$a specificita protilátek $x imunologie $7 D000918
650    _2
$a nádory prsu $x diagnóza $x imunologie $7 D001943
650    _2
$a nemalobuněčný karcinom plic $x diagnóza $x imunologie $7 D002289
650    _2
$a spinocelulární karcinom $x diagnóza $x imunologie $7 D002294
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a kultivované buňky $7 D002478
650    _2
$a zkřížené reakce $7 D003429
650    _2
$a DNA vazebné proteiny $x imunologie $7 D004268
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $x normy $7 D007150
650    _2
$a nádory plic $x diagnóza $x imunologie $7 D008175
650    _2
$a membránové proteiny $x chemie $x imunologie $7 D008565
650    _2
$a myši $7 D051379
650    _2
$a jaderné proteiny $x imunologie $7 D009687
650    _2
$a protein - isoformy $7 D020033
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a nádorový supresorový protein p53 $x imunologie $7 D016159
650    _2
$a nádorové supresorové proteiny $x imunologie $7 D025521
650    _2
$a nádory děložního čípku $x diagnóza $x imunologie $7 D002583
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Holčáková, Jitka $u - $7 xx0125776
700    1_
$a Nenutil, Rudolf $u - $7 xx0057842
700    1_
$a Stratmann, Rembert $u -
700    1_
$a Bouchalova, Pavla $u -
700    1_
$a Müller, Petr $u - $7 xx0036920
700    1_
$a Mouková, Lucie $u - $7 xx0098620
700    1_
$a Coates, Philip J $u -
700    1_
$a Vojtěšek, Bořivoj, $u - $d 1960- $7 xx0001694
773    0_
$w MED00004660 $t Virchows Archiv an international journal of pathology $x 1432-2307 $g Roč. 463, č. 3 (2013), s. 415-425
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23887585 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140401 $b ABA008
991    __
$a 20191021125709 $b ABA008
999    __
$a ok $b bmc $g 1018023 $s 849467
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 463 $c 3 $d 415-425 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
GRA    __
$a NT13794 $p MZ0
LZP    __
$a Pubmed-20140401

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace